COMP <GO>
JAZZ vs BBIO // ALTMAN Z-SCORE & DEBT/EQUITY
Jazz Pharmaceuticals plc (Ireland) (NASDAQ) VS. BridgeBio Pharma Inc. (NASDAQ) • 15-METRIC TALLY: JAZZ 7
— BBIO 4
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: JAZZ
LAST: $214.44 (-0.71%) • MKT CAP: $14.02B
balance-sheet
1.97
LAST: $75.00 (+0.06%) • MKT CAP: $14.60B
balance-sheet
0.45
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (JAZZ VS. BBIO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | JAZZ | BBIO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 95.80% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -4.70% | -35.00% | +30.30 | JAZZ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 9.61% | -3.23% | +12.84 | JAZZ | /fcf-yield <GO> |
| Operating Margin | -10.10% | -60.00% | +49.90 | JAZZ | /operating-margins <GO> |
| Net Profit Margin | -8.30% | -60.00% | +51.70 | JAZZ | /net-margins <GO> |
| Revenue Growth (YoY) | 4.90% | 126.30% | -121.40 | BBIO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 1.97 | 0.45 | +1.52 | JAZZ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 4/9 | +3.00 | JAZZ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.5 | 63.9 | -15.40 | BBIO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.09 | 1.00 | +0.09 | JAZZ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 36.0x | 33.0x | +3.00 | BBIO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $14.02B | $14.60B | -$580.1M | BBIO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | JAZZ REV | BBIO REV | JAZZ GROSS % | BBIO GROSS % | JAZZ FCF | BBIO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.27B | $502.1M | — | 95.8% | $1.30B | -$447.0M |
| FY 2024 | $4.07B | $221.9M | — | 98.3% | $1.36B | -$521.7M |
| FY 2023 | $3.83B | $9.3M | — | — | $919.5M | -$528.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
JAZZ // BETA 1.09
BBIO // BETA 1.00